UK: Business Deal Bruker Takes Over UK’s Optimal Industrial Automation and Technologies

Bruker has acquired Optimal Industrial Automation and Technologies which specializes in pharma and biopharma process analytical technology, pharma manufacturing automation and quality assurance software and systems integration. With this move, the company aims to become a vital software and solutions provider for small molecule, biologics and new drug modalities pharma companies.

Massachusetts/USA – Bruker Corporation has recently announced the acquisition of Optimal Industrial Automation and Technologies, a leader in pharma and biopharma process analytical technology (Pat), pharma manufacturing automation and Quality Assurance (QA) software and systems integration, based in the United Kingdom. The Optimal biopharma tools acquisition strengthens Bruker as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.

Financial details of the acquisition were not disclosed. Optimal’s 2022 revenue is expected to be approximately 10 million dollars, and Optimal’s revenue growth rate and operating margins are projected to be accretive to Bruker in 2023 and beyond.

The Optimal biopharma tools and automation capabilities complement Bruker’s innovative and differentiated high-value NMR, mass spectrometry, SPR, molecular spectroscopy and X-ray scientific instruments, and life-science solutions for biopharma drug discovery and development, as well as for Pat analytical and QA solutions. Together these biopharma tools enable Bruker’s global biopharma customers to bring efficacious and safe medicines to market more quickly.

Optimal has a focus on the automation and optimization of batch and continuous processes in the biopharma industry – from R&D to manufacturing. As an integrated Pat solutions provider, Optimal offers development, testing, deployment and support of quality-centric pharmaceutical production systems.

The Pat knowledge management software syntq can interface between multiple analytical instruments (spectral and univariate), multi-variate analysis (MVA) packages, manufacturing control systems and a range of adjacent software solutions to ensure quality in real-time.

As a 2021 Pharma Innovation Award winner, syntq is a proven enabler of quality-by-design via Pat. For users of syntq, this can significantly increase productivity and quality, while reducing waste, time-to-manufacture and time-to-market, with proven Optimal use cases tripling biopharma productivity.

While remaining a vendor-agnostic biopharma solutions provider, Optimal can integrate bioanalytical technologies such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and FTIR/NIR/Raman systems into innovative drug discovery, development, Pat and quality control workflows. Combining next-generation, high-performance technologies with Optimal solutions eases the transition from development to biopharma manufacturing, while remaining in regulatory compliance.

Dr. Falko Busse, President of the Bruker Biospin Group says, “The acquisition of Optimal is a very exciting step for Bruker as it supports more comprehensive solutions for the biopharmaceutical industry, now adding the capabilities to integrate cutting-edge systems into biopharma manufacturing processes and workflows.”

(ID:48176040)